SLC5A2 and diabetes mellitus: Now, the American Diabetes Association (ADA) has recommended in the Standards of Care in Diabetes the addition of GLP-1RAs and/or SGLT2 inhibitors (SGLT2i) to the treatment plan for patients with T2DM who have been diagnosed with or are at high risk of atherosclerotic cardiovascular disease (ASCVD) (3).